| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Laboratory of Immunobiology, National Cancer Institute, NIH, Bethesda, Maryland 20205
The effects of carrageenan and trypan blue on the expression of adoptive immunity to the syngeneic guinea pig line 10 hepatoma were investigated. Adoptive immunity was assessed by observing dermal tumor growth in recipients of immune cells and by bioassays in which tumor challenge sites were transplanted into secondary hosts. Carrageenan abrogated transferred immunity in treated animals as evidenced by dermal tumor growth and by development of fatal ascites tumors in peritoneal cavities of the secondary hosts. Trypan blue, on the other hand, did not abrogate transferred immunity in treated animals. However, the i.p. bioassay revealed the presence of line 10 cells in the tumor challenge sites 10 days after adoptive transfer. In vitro and in vivo exposure of immune spleen cells to carrageenan or trypan blue had no significant effect on the subsequent adoptive transfer, indicating that the inhibitory activity of these agents cannot be attributed to direct toxicity to immune lymphoid cells. Tumor challenge sites taken from carrageenan or trypan blue-treated animals 5 days after adoptive transfer failed to grow progressively when transplanted s.c. into secondary hosts. This observation suggests the presence of immune cells at tumor challenge sites. Thus, the inhibitory effects were unlikely due to interference with recirculation of the i.v.-transferred immune cells. Adoptive immunity was not influenced in guinea pigs that received a lethal dose of irradiation (500 rads). These results demonstrate that a recipient component(s) sensitive to carrageenan and trypan blue but resistant to radiation is essential to the expression of adoptive immunity.
1 This is the third publication in the series of investigations on immunological eradication of a syngeneic guinea pig tumor. For results of previous investigations, see Refs. 30 and 31.
2 To whom requests for reprints should be addressed, at Bldg. 560, R12-71, NCI-Frederick Cancer Research Facility, Frederick, Md. 21701.
3 Recipient of fellowship from Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior, Brazil. Present address: Instituto de Microbiologia, Ilha do Fundao, Rio de Janeiro, Brazil.
4 Present address: First Department of Medicine, Kyoto Prefectural University of Medicine, Kawaramachi-Hirokoji, Kamikyo-ku, Kyoto 602, Japan.
Received 10/12/82. Accepted 2/28/83.
This article has been cited by other articles:
![]() |
H. Nagata, T. Arai, Y. Soejima, H. Suzuki, H. Ishii, and T. Hibi Limited Capability of Regional Lymph Nodes to Eradicate Metastatic Cancer Cells Cancer Res., November 15, 2004; 64(22): 8239 - 8248. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |